CytoDyn Inc. CYDY · Stock Open CytoDyn Inc. in new tab
CytoDyn Inc. Analysis (CYDY)
Is CytoDyn Inc. a good investment? CytoDyn Inc. (CYDY) is currently trading at 0.2600 USD.
Earnings Schedule: CytoDyn Inc. is expected to release its next earnings report on July 29, 2026.
Investor FAQ
Does CytoDyn Inc. pay a dividend?
No, it does not currently pay a dividend.
What asset class is CytoDyn Inc.?
CytoDyn Inc. is classified as a Stock. You can compare it against 4 other assets in the "Related Symbols" list on this page.
When is the next earnings date?
The next earnings date is projected to be July 29, 2026.
Company Profile
CytoDyn Inc. operates as a clinical-stage biotechnology company. The company focuses on developing treatments for multiple therapeutic indications based on leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor in the areas of human immunodeficiency virus (HIV), non-alcoholic steatohepatitis (NASH), oncology, and such as coronavirus disease (COVID-19). It is also conducting a Phase 1b/2 clinical trial with leronlimab in metastatic triple-negative breast cancer. The company was formerly known as RexRay Corporation. CytoDyn Inc. was incorporated in 2002 and is based in Vancouver, Washington.
Community Discussion